drugset / Trial / NCT01055899

Safety Study of a Single Dose of REGN88(SAR153191)in Patients With Rheumatoid Arthritis

NCT01055899

Phase 1 Completed 15 enrolled Regeneron Pharmaceuticals Sanofi · collab
RandomizedSingle-groupQuadruple-blindTreatment

Summary

This study will test the safety and tolerability (how the body reacts to the drug) of REGN88 and placebo (an inactive substance that contains no medicine) in patients with Rheumatoid Arthritis.

Timeline

Start
2008-07
Primary completion
2009-03
Completion
2009-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Sarilumab Monoclonal antibody Subcutaneous

Indications